File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Update in management of hepatocellular carcinoma in Eastern population

TitleUpdate in management of hepatocellular carcinoma in Eastern population
Authors
KeywordsEvidence
Hepatocellular carcinoma
Liver cirrhosis
Management
Survival
Treatment
Update
Issue Date2015
PublisherBaishideng Publishing Group. The Journal's web site is located at http://www.wjgnet.com/1948-5182/index.htm
Citation
World Journal of Hepatology, 2015, v. 7 n. 11, p. 1562-1571 How to Cite?
AbstractHepatocellular carcinoma (HCC) is one of the commonest malignant tumours in the East. Although the management of HCC in the West is mainly based on the Barcelona Clinic for Liver Cancer staging, it is considered too conservative by Asian countries where the number of HCC patients is huge. Scientific and clinical advances were made in aspects of diagnosis, staging, and treatment of HCC. HCC is well known to be associated with cirrhosis and the treatment of HCC must take into account the presence and stage of chronic liver disease. The major treatment modalities of HCC include: (1) surgical resection; (2) liver transplantation; (3) local ablation therapy; (4) transarterial locoregional treatment; and (5) systemic treatment. Among these, resection, liver transplantation and ablation therapy for small HCC are considered as curative treatment. Portal vein embolisation and the associating liver partition with portal vein ligation for staged hepatectomy may reduce dropout in patients with marginally resectable disease but the midterm and long-term results are still to be confirmed. Patient selection for the best treatment modality is the key to success of treatment of HCC. The purpose of current review is to provide a description of the current advances in diagnosis, staging, preoperative liver function assessment and treatment options for patients with HCC in the east. © 2015 Baishideng Publishing Group Inc.
Persistent Identifierhttp://hdl.handle.net/10722/217271
ISSN
2023 Impact Factor: 2.5
2023 SCImago Journal Rankings: 0.673
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChu, KK-
dc.contributor.authorCheung, TT-
dc.date.accessioned2015-09-18T05:54:35Z-
dc.date.available2015-09-18T05:54:35Z-
dc.date.issued2015-
dc.identifier.citationWorld Journal of Hepatology, 2015, v. 7 n. 11, p. 1562-1571-
dc.identifier.issn1948-5182-
dc.identifier.urihttp://hdl.handle.net/10722/217271-
dc.description.abstractHepatocellular carcinoma (HCC) is one of the commonest malignant tumours in the East. Although the management of HCC in the West is mainly based on the Barcelona Clinic for Liver Cancer staging, it is considered too conservative by Asian countries where the number of HCC patients is huge. Scientific and clinical advances were made in aspects of diagnosis, staging, and treatment of HCC. HCC is well known to be associated with cirrhosis and the treatment of HCC must take into account the presence and stage of chronic liver disease. The major treatment modalities of HCC include: (1) surgical resection; (2) liver transplantation; (3) local ablation therapy; (4) transarterial locoregional treatment; and (5) systemic treatment. Among these, resection, liver transplantation and ablation therapy for small HCC are considered as curative treatment. Portal vein embolisation and the associating liver partition with portal vein ligation for staged hepatectomy may reduce dropout in patients with marginally resectable disease but the midterm and long-term results are still to be confirmed. Patient selection for the best treatment modality is the key to success of treatment of HCC. The purpose of current review is to provide a description of the current advances in diagnosis, staging, preoperative liver function assessment and treatment options for patients with HCC in the east. © 2015 Baishideng Publishing Group Inc.-
dc.languageeng-
dc.publisherBaishideng Publishing Group. The Journal's web site is located at http://www.wjgnet.com/1948-5182/index.htm-
dc.relation.ispartofWorld Journal of Hepatology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectEvidence-
dc.subjectHepatocellular carcinoma-
dc.subjectLiver cirrhosis-
dc.subjectManagement-
dc.subjectSurvival-
dc.subjectTreatment-
dc.subjectUpdate-
dc.titleUpdate in management of hepatocellular carcinoma in Eastern population-
dc.typeArticle-
dc.identifier.emailCheung, TT: cheung68@hku.hk-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.4254/wjh.v7.i11.1562-
dc.identifier.pmid26085915-
dc.identifier.pmcidPMC4462694-
dc.identifier.scopuseid_2-s2.0-84930852131-
dc.identifier.hkuros254808-
dc.identifier.volume7-
dc.identifier.issue11-
dc.identifier.spage1562-
dc.identifier.epage1571-
dc.identifier.isiWOS:000439196600012-
dc.publisher.placeUnited States-
dc.identifier.issnl1948-5182-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats